Skip To Main Content
Yariswamy Manjunath on Muck Rack

Yariswamy Manjunath

As seen in: BioRxiv, Cell Press, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yariswamy

Contact Yariswamy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Characterization of A Bronchoscopically Induced Transgenic Lung Cancer Pig Model for Human Translatability

|
By Kanve Nagaraj Suvilesh, Nagabhishek Sirpu Natesh, Yariswamy Manjunath, Kirtan Joshi
| BioRxiv
Abstract Background: There remains a need for animal models with human translatability in lung cancer (LC) research. Findings in pigs have high impact on humans due to similar anatomy and physiology. We present the characterization of a bronchoscopically-induced LC model in Oncopigs carrying inducible KRASG12D and TP53R167H mutations. Methods: Twelve Oncopigs underwent 29 injections via flexible bronchoscopy.
Open in Who Shared Issue with article?

Induction of Ferroptosis by an Amalgam of Extracellular Vesicles and Iron Oxide Nanoparticles Overcomes Cisplatin Resistance in Lung Cancer

|
By Anjugam Paramanantham, Rahmat Asfiya, Yariswamy Manjunath, Lei Xu
| BioRxiv
Abstract Extracellular vesicles (EVs) hold potential as effective carriers for drug delivery, providing a promising approach to resolving challenges in lung cancer treatment. Traditional treatments, such as with the chemotherapy drug cisplatin, encounter resistance in standard cell death pathways like apoptosis, prompting the need to explore alternative approaches.
Open in Who Shared Issue with article?

Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugs

|
By Kanve N. Suvilesh, Yariswamy Manjunath, Yulia I Nussbaum, Mohamed Gadelkarim
| BioRxiv
Abstract Background: The five-year survival for non-metastatic non-small cell lung cancer (NSCLC) patients undergoing curative surgery remains poor at ~50% that is due to locoregional and/or distant metastatic recurrences. Patient-derived tumor organoids (PDTOs) have high potential as clinically relevant high-throughput drug testing platforms to personalize and improve treatment of NSCLC patients.
Open in Who Shared Issue with article?
See all 8 articles